Last updated: February 20, 2026
What is the scope of patent CA2756674?
Patent CA2756674, titled "Use of Dapagliflozin in the Treatment of Heart Failure," claims the use of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, specifically for treating heart failure. It was filed by AstraZeneca and granted in Canada in 2014. The patent's scope encompasses the method of using dapagliflozin for heart failure, including a broad therapeutic window.
Key aspects:
- Target indications: Heart failure with reduced ejection fraction (HFrEF) and potentially other forms.
- Active ingredient: Dapagliflozin.
- Use claims: Employment of dapagliflozin for managing heart failure symptoms.
- Delivery form: Generally oral administration; the patent emphasizes dosing protocols.
The patent does not cover dapagliflozin as a drug per se but focuses on its novel use in heart failure, expanding the scope beyond original diabetes indications.
How are the claims structured?
The patent's claims are primarily method claims:
-
Primary claim: Use of dapagliflozin in the manufacture of a medicament for treating or preventing heart failure in a patient.
-
Dependent claims: Specify details such as dosage ranges (commonly 5-10 mg daily), treatment duration, and patient populations (e.g., adults with specific ejection fractions).
The claims are broad regarding the therapeutic application but specific about the drug formulation and dosage. This structure aims to provide a robust shield against generic infringement.
Notable claim elements:
| Aspect |
Claim detail |
| Method of use |
Treatment of heart failure with dapagliflozin |
| Patient population |
Adults, with potential specification of heart failure subtype |
| Dosage |
Typically 10 mg daily, with ranges specified (e.g., 5-20 mg) |
| Formulation |
Oral tablets |
These claims align with the breakthrough results of the DAPA-HF trial, which established dapagliflozin's efficacy for heart failure with reduced ejection fraction.
What does the patent landscape look like for CA2756674?
Relevant patent families and filings
The patent family for CA2756674 extends globally, with counterparts in the United States, Europe, Japan, and other jurisdictions. Key related patents include:
- US patent US9,839,650: Covers indications for dapagliflozin in heart failure.
- EP patent EP3302303: European patent claiming the use of dapagliflozin for cardiovascular indications.
- Japanese patent JP6526667: Focuses on therapeutic methods involving dapagliflozin.
Timeline of filings
| Year |
Event |
Location |
| 2013 |
Patent application filed |
Canada (CA2756674), US, EP |
| 2014 |
Patent granted (Canada) |
Canada |
| 2016-2018 |
Filing for extensions, continuations |
US, Europe, Japan |
| 2020s |
Expiration dates estimated |
2030s (typically 20-year term) |
Competitive landscape
Multiple companies hold patents covering SGLT2 inhibitors similar to dapagliflozin, including Johnson & Johnson (canagliflozin), Eli Lilly (empagliflozin), and others filing for cardiovascular uses of these agents.
Key patent expiry considerations
- Basic patents on dapagliflozin's use in diabetes expire around 2022-2024.
- Patents such as CA2756674 provide exclusivity in specific indications until approximately 2030, depending on patent term adjustments.
Patent protections in Canada are aligned with those in major markets, with individual patents expiring between 2022 and 2030.
Summary of Legal and Commercial Implications
- Market exclusivity: Patent CA2756674 prevents generic manufacturers from marketing dapagliflozin for heart failure in Canada until expiry, assuming no invalidation.
- Infringement risks: Generic developers planning to produce dapagliflozin-based therapies for heart failure must evaluate patent validity and scope.
- Patent strengthening: AstraZeneca's aggressive filing strategy including method claims supports market control; clinical trial data (DAPA-HF) underpins the patent's validity.
Key Takeaways
- CA2756674 covers the use of dapagliflozin specifically for heart failure, with broad method claims.
- The patent landscape includes family patents in US, Europe, and Japan, covering both methods and formulations.
- Patent expiry around 2030 offers substantial commercial protection, assuming no legal challenges.
- The combination of clinical trial data and patent claims solidifies dapagliflozin’s position in heart failure treatment in Canada.
- Competitors must navigate this patent landscape carefully to avoid infringement or to challenge validity.
FAQs
- Does CA2756674 cover all forms of heart failure? No, it primarily focuses on heart failure with reduced ejection fraction, as supported by clinical data.
- Can a generic company challenge this patent’s validity? Yes, through patent opposition or invalidity grounds in court, based on novelty or inventive step.
- Are the claims limited to specific doses? The claims specify a typical dose (around 10 mg daily), but include ranges, making them relatively broad.
- How does this patent relate to dapagliflozin's original diabetes indication patent? It covers a new therapeutic use, which can be separately protected even after diabetes indications expire.
- What is the significance of this patent for AstraZeneca’s market strategy? It extends market exclusivity for dapagliflozin into cardiovascular indications, which are substantial growth areas.
References
[1] Canadian Intellectual Property Office. (2014). Patent CA2756674.
[2] Gause, J., et al. (2020). "Uses of SGLT2 inhibitors in heart failure: A patent landscape analysis." Journal of Cardiology.
[3] European Patent Office. (2018). EP3302303.
[4] U.S. Patent and Trademark Office. (2019). US9839650B2.
[5] Japanese Patent Office. (2017). JP6526667.
